Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports

Regulatory Toxicology and Pharmacology

Volumn 61, Issue 3, 2011, Pages 282-291

  Teschke, Rolf ^a   Glass, Xaver ^b   Schulze, Johannes ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Chelidonium majus; Chelidonium majus hepatotoxicity; Greater Celandine; Greater Celandine hepatotoxicity; Herb induced liver injury; Herbal hepatotoxicity

Indexed keywords

HERBACEOUS AGENT;

ADULT; AGED; ARTICLE; CAUSAL ATTRIBUTION; CHELIDONIUM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; GERMANY; HUMAN; JAUNDICE; LIVER INJURY; LIVER TOXICITY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; AGED; CHELIDONIUM; DRUG-INDUCED LIVER INJURY; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS;

CHELIDONIUM; CHELIDONIUM MAJUS;

EID: 80855130652     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.08.008     Document Type: Article

References (59)

1. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., García-Muñoz B., Gonzalez-Grande R., Pizarro A., Durán J.A., Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., Borras A., Soler A., Salmerón J., Martin-Vivaldi R. Spanish group for the study of drug-induced liver disease. Drug-induced liver injury, 2005. An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
2. Au J.S., Navarro V.J., Rossi S. Review article: drug induced liver injury - its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther. 2011, 34:11-20.
3. Batchelor W.B., Heathcote J., Wanless I.R. Chaparral-induced hepatic injury. Am. J. Gastroenterol. 1995, 90:831-833.
4. Bénichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46:1331-1336.
5. Benninger J., Schneider H.T., Schuppan D., Kirchner T., Hahn E.G. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Gastroenterology 1999, 117:1234-1237.
6. Beuers U., Spengler U., Pape G.R. Hepatitis after chronic abuse of senna. Lancet 1991, 337:372-373.
7. BfArM, 2002. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany. Rejection of Drug Risks, Step II. As related to: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. June 14, 2002. (accessed 15.08.11). http://www.spc.int/cis/documents/02_0714_BfArM_Kava_Removal.pdf.
8. BfArM, 2005a. Bundesinstitut für Arzneimittel und Medizinprodukte: Bekanntmachung. Abwehr von Gefahren durch Arzneimittel, Stufe II, Anhörung: Schöllkraut-haltige Arzneimittel zur innerlichen Anwendung. May 6, 2005. (accessed 15.08.11). http://www.bfarm.de/cae/servlet/contentblob/1014620/publicationFile/66198/schoellkraut-anhoerung_050505.pdf.
9. BfArM, 2005b. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany. Kava-Kava. May 12, 2005. Available at: (accessed 15.08.11). http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/functions/2005/risikoinfo-2005-node.html.
10. Colin-Johnes D.G., Harvey J. Mistletoe hepatitis. Br. Med. J. 1982, 284:744-745.
11. Conti E., De Checchi G., Mencarelli R., Pinato S., Rovere P. Lycopodium similiaplex-induced acute hepatitis: a case report. Eur. J. Gastroenterol. Hepatol. 2008, 20:469-471.
12. Crijns A.P.G., de Smet P.A.G.M., van den Heuvel M., Schot B.W., Haagsma E.B. Acute hepatitis after use of herbal preparation with Greater Celandine (Chelidonium major). Ned. Tijdschr. Geneeskd. 2002, 146:124-128. (article in Dutch).
13. Danan G., Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin.Epidemiol. 1993, 46:1323-1330.
14. Davies E.G., Pollock I., Steel H.M. Chinese herbs for eczema. Lancet 1990, 336:117.
15. Elinav E., Pinkser G., Safadi R., Pappo O., Bromberg M., Anis E., Keinan-Boker L., Broide E., Ackerman Z., Kaluski D.N., Lev B., Shouval D. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J. Hepatol. 2007, 47:514-520.
16. EMA, 2007. European Medicines Agency: Assessment of case reports connected to herbal medicinal products containing cimicifugae racemosae rhizoma (black cohosh, root). Issued May 8, 2007. (accessed 15.08.11). http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2010/02/WC500074167.pdf.
17. García-Cortés M., Lucena M.I., Pachkoria K., Borraz Y., Hidalgo R., Andrade R.J. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 2008, 27:780-789.
18. Greving I., Meister V., Monnerjahn C., Müller K.M., May B. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol. Drug Saf. 1998, 7:S66-S69.
19. Gunawan B., Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 2004, 36:301-312.
20. Hardeman E., van Overbeke L., Ilegems S., Ferrante M. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Acta Gastroenterol. Belg. 2008, 71:281-282.
21. Horowitz R.S., Feldhaus K., Dart R.C., Stermitz F.R., Beck J.J. The clinical spectrum of Jin Bu Huang toxicity. Arch. Intern. Med. 1996, 156:899-903.
22. Itoh S., Marutani K., Nishijima T., Matsuo S., Itabashi M. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tang). Dig. Dis. Sci. 1995, 40:1845-1848.
23. Kane J.A., Kane S.P., Jain S. Hepatitis induced by traditional Chinese herbs; possible toxic components. Gut 1995, 36:146-147.
24. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33:308-310.
25. Laliberté L., Villeneuve J.P. Hepatitis after the use of Germander, a herbal remedy. Can. Med. Assoc. J. 1996, 154:1689-1692.
26. Larrey D., Vial T., Pauwels A., Castot A., Biour M., David M., Michel H. Hepatitis after Germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 1992, 117:129-132.
27. Liss G., Lewis J.H. Drug-induced liver injury: what was new in 2008?. Expert Opin. Drug Metab. Toxicol. 2009, 5:843-860.
28. Mahady G.B., Low Dog T., Barrett M.L., Chavez M.L., Gardiner P., Ko R., Marles R.J., Pellicore L.S., Giancaspro G.I., Sarma D.N. United States Pharmacopeia reviewof the black cohosh case reports of hepatotoxicity. Menopause 2008, 15:628-638.
29. Moro P.A., Cassetti F., Giugliano G., Falce M.T., Mazzanti G., Menniti-Ippolito F., Raschetti R., Santuccio C. Hepatitis from Greater Celandine (Chelidonium majus L.): Review of literature and report of a new case. J. Ethnopharmacol. 2009, 124:328-332.
30. Nadir A., Agrawal S., King P.D., Marshall J.B. Acute hepatitis associated with the use of a Chinese herbal product, Ma-huang. Am. J. Gastroentol. 1996, 91:1436-1438.
31. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., Janecek E., Domecq C., Greenblatt D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30:239-245.
32. Navarro V.J. Herbal and dietary supplement hepatotoxicity. Semin. Liver Dis. 2009, 24:373-382.
33. Perharic-Walton L., Murray V. Toxicity of traditional Chinese herbal remedies. Lancet 1992, 340:674.
34. Rifai K., Flemming P., Manns M.P., Trautwein C. Severe drug hepatitis caused by Chelidonium majus. Internist 2006, 47:749-751.
35. Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liangpunsakul S., Watkins P.B., Davern T., McHutchison J.G. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008, 48:1175-1183. Drug-Induced Liver Injury Network (DILIN).
36. Rockey D.C., Seeff L.B., Rochon J., Freston J., Chalasani N., Bonachini M., Fontana R.J., Hayashi P.H. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126. US Drug-induced Liver Injury Network.
37. Sarma D.N., Barrett M.L., Chavez M.L., Gardiner P., Ko R., Mahady G.B., Marles R.J., Pellicore L.S., Giancaspro G.I., Low Dog T. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf. 2008, 31:469-484.
38. Schmidt M., Morgan M., Bone K., McMillan J. Kava: a risk-benefit assessment. The Essential Guide to Herbal Safety 2005, 155-221. Elsevier Churchill Livingstone, St. Louis (Missouri). M. Mills, K. Bone (Eds.).
39. Schoepfer A.M., Engel A., Fattinger K., Marbet U.A., Criblez D., Reichen J., Zimmermann A., Oneta C.M. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife® products. J. Hepatol. 2007, 47:521-526.
40. Schulze J., Raasch W., Siegers C.P. Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine 2003, 10(Suppl. IV):68-73.
41. Seeff L.B. Herbal hepatotoxicity. Clin. Liv. Dis. 2007, 11:577-596.
42. Stickel F., Pöschl G., Seitz H.K., Waldherr R., Hahn E.G., Schuppan D. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand. J. Gastroenterol. 2003, 38:565-568.
43. Stine J.G., Lewis J.H. Drug-induced liver injury: a summary of recent advances. Expt. Opin. Drug Metab. Toxicol. 2011, 7:875-890.
44. Strahl S., Ehret V., Dahm H.H., Maier K.P. Necrotizing hepatitis after taking herbal medication (extracts of kava or of common or lesser celandine). Dtsch. Med. Wschr. 1998, 123:1410-1414. (article in German).
45. Tarantino G., Di Minno M.N.D., Pezullo M.G., Pezzullo L.S., Milone F., Milone M., Capone D. Drug-induced liver injury due to " natural products" used for weight loss: A case report. World J. Gastroenterol. 2009, 15:2414-2417.
46. Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann. Hepatol. 2009, 8:184-195.
47. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 2010, 30:1270-1279.
48. Teschke R. Kava hepatotoxicity - A clinical review. Ann. Hepatol. 2010, 9:251-265.
49. Teschke R., Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: A structured causality assessment. Ann. Hepatol. 2009, 8:258-266.
50. Teschke R., Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?. Regul. Tox. Pharmacol. 2011, 59:1-7.
51. Teschke R., Schwarzenboeck A., Hennermann K.H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br. J. Clin. Pharmacol. 2008, 66:758-766.
52. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20:1182-1193.
53. Teschke R., Schmidt-Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?. Pharmacoepidemiol. Drug Saf. 2011, 20:567-582.
54. Teschke R., Schwarzenboeck A., Schmidt-Taenzer W., Wolff A., Hennermann K.H. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann. Hepatol. 2011, 11:249-259.
55. Valente G., Sanges M., Campione S., Bellevicine C., De Franchis G., Sollazzo R., Matera D., Cimino L., Vecchione R., D'Arienzo A. Herbal hepatotoxicity: a case of difficult interpretation. Eur. Rev. Med. Pharmacol. Sci. 2010, 14:865-870.
56. WHO, 2000. World Health Organization. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC), Database. (accessed 15.08.11). http://www.who-umc.org/DynPage.aspx?id=22682.
57. World Health Organization. Assessments of the risk of hepatotoxicity with kava products 2007, WHO, WHO Document Production Services, Geneva, Switzerland.
58. Woolf G.M., Petrovic L.M., Rojter S.E., Wainwright S., Villamil F.G., Katkov W.N., Michieletti P., Wanless I.R., Stermitz F.R., Beck J.J., Vierling J.M. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann. Intern. Med. 1994, 121:729-735.
59. Zimmerman H.J. Hepatotoxicity 1999, Lippincott Williams & Wilkins, Philadelphia.